Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 12:56 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 364 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Influenza vaccination Clear all

Conditions: Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
Interventions: CAR T Cells; Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2040
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Influenza, Vaccine Hesitancy
Interventions: Text messaging; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 6 Months and older
Enrollment: 228,831 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Influenza
Interventions: High-Fiber Diet (HFD), Prebiotic Food-Enriched Diet (PreFED); Dietary Supplement
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2029
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Viral Vaccines
Interventions: Inactivated influenza vaccine; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza Immunization, Healthy Volunteers
Interventions: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months and older
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Bardstown, Kentucky • Salt Lake City, Utah

Conditions: Influenza
Interventions: Pumarix™, Pandemrix ™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 780 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 7
States / cities: Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more

Conditions: Seasonal Influenza
Interventions: Planning Prompt, Default Appointment, Control; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Influenza, Influenza -Like Illness, Influenza, Human
Interventions: Recombinant Influenza Vaccine, Standard Dose Quadrivalent Influenza Vaccine; Biological
Lead sponsor: Insight Therapeutics, LLC; Other
Eligibility: 18 Years to 120 Years
Enrollment: 1,989 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Influenza, Healthy
Interventions: Fluzone®, FluMist®; Biological
Lead sponsor: Stanford University; Other
Eligibility: 6 Months to 10 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Stanford, California

Conditions: Influenza
Interventions: Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 64 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Influenza, Human
Interventions: Functional Proximity, Base Proximity; Other
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 1,801 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: Trivalent inactivated influenza vaccine; Biological
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Durham, North Carolina

Conditions: Influenza, Vaccination
Interventions: Text message influenza vaccine reminders; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 6 Months to 8 Years
Enrollment: 2,105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 3
States / cities: Itasca, Illinois • New York, New York • Philadelphia, Pennsylvania

Conditions: Flu Vaccine
Interventions: Fluzone-High Dose Quadrivalent, Fluad, Flublock; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 65 Years to 125 Years
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Rheumatologic Disorder, Inflammatory Bowel Diseases, Immune Complex Diseases
Interventions: Influenza vaccine; Biological
Lead sponsor: Stony Brook University; Other
Eligibility: 3 Years to 22 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: East Setauket, New York

Conditions: Influenza
Interventions: Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine; Biological
Lead sponsor: Alachua Government Services, Inc.; Industry
Eligibility: 18 Years to 49 Years
Enrollment: 353 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Huntsville, Alabama • Melbourne, Florida • Peoria, Illinois + 2 more

Conditions: Immunology, Healthy Adults
Interventions: trivalent inactivated influenza vaccine (TIV), nonavalent HPV vaccine (HPV), hepatitis A (HAV) vaccines, tetanus, diphtheria and acellular pertussis vaccine (Tdap); Biological
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Astrocytoma, Glioma, Oligodendroglioma
Interventions: Hepatitis A Vaccine, Laboratory Biomarker Analysis, Tetanus Toxoid Vaccine, Trivalent Influenza Vaccine; Biological · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Young Adults, Influenza Vaccines, Influenza Vaccine Response
Interventions: FluMist, inactivated influenza vaccine, bronchoscopy; Biological · Procedure
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 40 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Influenza
Interventions: GSK Biologicals' FluLaval®, Placebo (saline), GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A, GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 19 Years to 40 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 3
States / cities: Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Influenza
Interventions: Community-based vaccine outreach intervention; Biological
Lead sponsor: The New York Academy of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza, Virus Diseases
Interventions: H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 49 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Human Influenza
Interventions: Standard dose influenza vaccination, High dose influenza vaccination; Biological
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Mucosal Immunity
Interventions: Fluzone; Drug
Lead sponsor: John Sundy; Other
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Durham, North Carolina

Search by objective public record fields.

CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Precision Vaccine Promotion in Underserved Populations

Impact of High Dietary Fiber on Microbiome and Vaccine Responses

Flu Vaccine Responses in the Setting of Melanoma Treatment

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

The Effect of Time-Slot Scheduling on Flu Vaccination Rates

Recombinant Influenza Vaccination in U.S. Nursing Homes

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection

Cellular and Humoral Immune Response to Primary and Secondary Immunization With Subvirion H5N1 Vaccines

The Effect of Proximity on Flu-Shot Participation

Feasibility of Cocooning Immunization Strategy With Influenza Vaccine

Flu2Text: Text Message Reminders for 2nd Dose of Influenza Vaccine

Senescent Immunity in Elders and Vaccine Responses (SILVER)

Flu Vaccine Response in Patients on Biologic Therapies

Reverse Genetic H9N2 Influenza Vaccine Study in Adults

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

Qualitative, Qualitative, and Functional Studies Over the First Year in Measuring Immune System Response During the First Year of Therapy in Patients With Brain Tumors

Characterizing the Human Airway Immune Response to FluMist Vaccination

Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults

Rapid Vaccination of Hard-To-Reach Populations

Single Group Study of the Safety of and Immune Response to a Bird Flu Virus Vaccine (H5N1) in Healthy Adults

Tfh Dysfunction in HIV and Aging

Strategies for Enhancing Mucosal Immunity to Influenza Vaccine